Amicus spins out gene therapy unit in SPAC deal as it pivots efforts toward Pompe disease program
A rare disease biotech out of Philadelphia is spinning out its gene therapy unit to reverse merge with a blue-chip SPAC.
Amicus Therapeutics will send off its gene therapy component in a new company called Caritas Therapeutics, which will partner with Perceptive’s fourth blank-check outfit and head to Nasdaq, the biotech announced Wednesday morning. Caritas will get about $400 million overall in the deal, including approximately $150 million held in ARYA Sciences Acquisition Corp IV, a $200 million PIPE investment and a $50 million cash investment from Amicus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
